Pfizer Offer of 6,000p/Shr for Astra Still Accretive, BNP Says
2014-06-24 09:46:27.572 GMT
By Allison Connolly
June 24 (Bloomberg) -- Deal makes economic sense on cost
synergies, tax perspective, BNP Paribas says in a note.
* Says sweetened offer of 6,000p would still be accretive,
boost Pfizer’s 2016 earnings by 13% and create value
* Notes Astra can renew talks with Pfizer as soon as Aug.; new
bid not allowed before Nov.
* NOTE: June 20, AstraZeneca Looking to Enhance Takeover
Defense, FT Says
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
--With assistance from Gaurav Panchal in London.
To contact the reporter on this story:
Allison Connolly in London at +44-20-3525-7043 or
aconnolly4@bloomberg.net
To contact the editor responsible for this story:
James Ludden at +44-20-7673-2645 or
jludden@bloomberg.net
2014-06-24 09:46:27.572 GMT
By Allison Connolly
June 24 (Bloomberg) -- Deal makes economic sense on cost
synergies, tax perspective, BNP Paribas says in a note.
* Says sweetened offer of 6,000p would still be accretive,
boost Pfizer’s 2016 earnings by 13% and create value
* Notes Astra can renew talks with Pfizer as soon as Aug.; new
bid not allowed before Nov.
* NOTE: June 20, AstraZeneca Looking to Enhance Takeover
Defense, FT Says
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
--With assistance from Gaurav Panchal in London.
To contact the reporter on this story:
Allison Connolly in London at +44-20-3525-7043 or
aconnolly4@bloomberg.net
To contact the editor responsible for this story:
James Ludden at +44-20-7673-2645 or
jludden@bloomberg.net